Clinical trials: Oropharyngeal Cancer
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer
- Trial name
- NCT01044433
- Testing
- lapatinib ditosylate, capecitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
The diagnostic and pre-therapeutic assessment of squamous cell carcinomas requires a neck and chest CT scan and a neck and facial MRI, which is the most effective examination, to establish the TNM stage of the tumor.
- Trial name
- DECT-CEco (NCT07343271)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Xerostomia
Mesenchymal Stemcells for Radiation Induced Xerostomia
The current study aims to assess the safety and feasibility of the injection of autologous adipost tissue derived MSCs on radiation-induced salivary gland hypofunction and xerostomia in head and neck cancer participants.
- Trial name
- MESRIX (NCT02513238)
- Testing
- Mesenchymal stem cell, Isotonic NaCl
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
The purpose of the study is to assess in a randomized, double blind, controlled, multi-center, phase III study, the efficacy of low level diode laser (100 MW, 658 Nm), in the prevention and treatment of radiochemotherapy-induced…
- Conditions
- Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx, Oral Mucositis
- Trial name
- LaserMucite (NCT01772706)
- Testing
- low level laser therapy
- Where
- 6 sites in France
- Volunteers
- 97 people
- Sponsor
- Institut Cancerologie de l'Ouest
Head and Neck Cancer
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002735
- Testing
- Induction chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00387335
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer.
- Trial name
- NCT05387915
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
This study will compare TNFE-NBI and biopsy, with DRE and biopsy for the diagnostic evaluation and staging of patients with suspicious UADT lesions.
- Conditions
- Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal, Oropharyngeal Cancer, Neoplasms, Hypopharyngeal
- Trial name
- TNFE-NBI (NCT01175499)
- Testing
- Direct Rigid Endoscopy, Transnasal Flexible Endoscopy with Narrowband Imaging
- Sponsor
- University of California, San Francisco
Neurocognitive Impairment, Delirium
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.
- Conditions
- Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00533884
- Testing
- Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Vanderbilt University Medical Center
HPV-Related Oropharynx Squamous Cell Carcinoma
The Minimalist Trial-2
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA.
- Trial name
- MINT-2 (NCT06702033)
- Testing
- Radiation therapy, Cisplatin, Surgery
- Where
- 3 sites in United States
- Volunteers
- 142 people
- Sponsor
- Washington University School of Medicine
Squamous Cell Carcinoma of the Oropharynx
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodigestive Tract (UAT) have a…
- Trial name
- iMonitORL (NCT06061705)
- Testing
- Tumor Biopsy
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Head and Neck Cancer
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004865
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Solid Tumor, Breast Cancer
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. St. John's wort may interfere with the effectiveness of chemotherapy.
- Conditions
- Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer
- Trial name
- NCT00041171
- Testing
- Hypericum perforatum, docetaxel
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Cancer
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01466244
- Testing
- cetuximab, cisplatin, gene expression analysis
- Volunteers
- 42 people
- Sponsor
- Eastern Cooperative Oncology Group
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Sintilimab) with targeted therapy (Cetuximab) as a possible treatment before and after surgery for locally…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT07079410)
- Testing
- Sintilimab+Cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Cancer, Xerostomia
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth).
- Trial name
- NCT00656513
- Testing
- Pilocarpine, ALTENS
- Where
- 20 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Radiation Therapy Oncology Group
Oropharyngeal Cancer
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
To determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx.
- Trial name
- NCT02159703
- Testing
- TORS, Adjuvant Radiation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may kill any remaining tumor cells.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00095641
- Testing
- capecitabine, adjuvant therapy, chemotherapy
- Sponsor
- SWOG Cancer Research Network
Stomatitis, Radiation Effects
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally…
- Trial name
- NCT00051441
- Testing
- Benzydamine Hydrochloride 0.15% Oral Rinse
- Volunteers
- 605 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
This pilot phase I trial studies how well durvalumab given with or without metformin works in treating participants with head and neck squamous cell carcinoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03618654
- Testing
- Metformin, Durvalumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University